Overview
The goal of this clinical trial is to use a novel virtual reality intervention to test for efficacy in reducing stimulant use and increasing abstinence, with concomitant increases in future self-identification, future time perspective, and delay-of-reward, in early recovering stimulant use disorder (StUD) persons. The main question[s] this trial aims to answer are:
- Will the Virtual Reality (VR) intervention decrease the number of stimulant use days?
- Will the VR intervention produce longer abstinence periods during follow-up visits?
- Will the VR intervention increase stimulant drug abstinence rates?
- Will the VR intervention increase future self-identification?
- Will the VR intervention increase self-reported future time perspective?
- Will the VR intervention increase preference for delayed rewards in a laboratory delay discounting task on the study day?
- Will the VR intervention produce gains in the behavioral effects of future self-identification, future time perspective, and delayed rewards at the 30-day and 6-month follow-ups?
Researchers will compare the experimental and control groups to see if there are differences in the results for the questions outlined above.
Eligibility
Inclusion Criteria:
- Abstinence between ≥14 days and ≤1 year
- At least 18 years old
- Verbal endorsement of commitment to recovery
- Outpatient
- Psychotropic drugs for SUD-comorbidity
- Drug/alcohol abstinence ≥ 24 hours at the time of the study day visit
- English comprehension
Exclusion Criteria:
- Unstable medical disorders
- Less than 18 years old
- Habitual drug use
- Mu-opioid drugs
- Smell/taste disorders
- Unstable psychiatric conditions
- Extravagant/elaborate face tattoos